Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer

Irinophore C™ (IrC™), extends the bioavailability of the active form of irinotecan, is more efficacious, and has little systematic toxicity. Cancer cells in primary orthotopic colon cancer tumors are obliterated with 6 cycles of IrC™ treatment (H&E sections).216